CBRE Facilitates Sale of Arkansas Medical Outpatient Building 

by Kate Humphrey | Apr 7, 2026 3:56 pm | Medical Outpatient Buildings

CBRE announced that it facilitated the sale of a medical outpatient building (MOB) in Little Rock, Arkansas. The buyer was The Laramar Group, and the seller was Catalyst Healthcare Real Estate.  The MOB, Kanis Medical Plaza, comprises 37,862 square feet. The building is 100% leased to... Read More »

Smile Partners USA Announces Fourth Partnership of 2026 

by Kate Humphrey | Apr 7, 2026 10:24 am | Physician Medical Groups

Smile Partners USA, backed by Silver Oak Services Partners, announced that it completed its fourth partnership of the year with the purchase of Favia Family Dental.  Favia Family Dental is a dental practice located in Arlington Heights, Illinois, just outside of Chicago. According to its website, the practice has two... Read More »

Sidekick Therapy Partners Expands in Tennessee

by Dylan Sammut | Apr 6, 2026 4:12 pm | Behavioral Health Care

Sidekick Therapy Partners, one of the largest speech pathology companies in the Appalachian region, has acquired Word of Mouth Clinical Associates, expanding its presence in the Brentwood area. Word of Mouth Clinical Associates provides speech-language therapy services in the Middle Tennessee area and employs around 10 speech-language... Read More »

CEO Scotte Hudsmith’s View on Specialized Dental Partners’s Acquisition Strategy

by Kate Humphrey | Apr 6, 2026 4:00 pm | Physician Medical Groups, Private Equity

Specialized Dental Partners (SDP) is one of the most active buyers in the dental practice market, announcing multiple transactions per year. A portfolio company of Quad-C Management, SDP is a leading specialty dental service organization that provides comprehensive support services to endodontic specialists across the United States. According to... Read More »

Neurocrine Acquires Soleno Therapeutics for $2.9 Billion 

by Kate Humphrey | Apr 6, 2026 3:54 pm | Biotechnology

On April 6, Neurocrine Biosciences, Inc. reported that it was expanding its endocrinology and rare disease portfolio with the purchase of Soleno Therapeutics, Inc. Neurocrine Biosciences will acquire Soleno Therapeutics for $53.00 per share in cash, representing a total transaction equity value... Read More »